These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36336690)

  • 21. Motivations for people with cognitive impairment to complete an advance research directive - a qualitative interview study.
    Jongsma K; Perry J; Schicktanz S; Radenbach K
    BMC Psychiatry; 2020 Jul; 20(1):360. PubMed ID: 32641010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study.
    Wilkins CH; Windon CC; Dilworth-Anderson P; Romanoff J; Gatsonis C; Hanna L; Apgar C; Gareen IF; Hill CV; Hillner BE; March A; Siegel BA; Whitmer RA; Carrillo MC; Rabinovici GD
    JAMA Neurol; 2022 Oct; 79(11):1139-47. PubMed ID: 36190710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of advance directives among nursing home residents with dementia.
    Huang HL; Shyu YL; Weng LC; Chen KH; Hsu WC
    Int Psychogeriatr; 2018 Mar; 30(3):341-353. PubMed ID: 28849756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units.
    Lage C; Suarez AG; Pozueta A; Riancho J; Kazimierczak M; Bravo M; Jimenez Bonilla J; de Arcocha Torres M; Quirce R; Banzo I; Vazquez-Higuera JL; Rabinovici GD; Rodriguez-Rodriguez E; Sánchez-Juan P
    J Alzheimers Dis; 2018; 63(3):1025-1033. PubMed ID: 29710706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
    Rabinovici GD; Gatsonis C; Apgar C; Chaudhary K; Gareen I; Hanna L; Hendrix J; Hillner BE; Olson C; Lesman-Segev OH; Romanoff J; Siegel BA; Whitmer RA; Carrillo MC
    JAMA; 2019 Apr; 321(13):1286-1294. PubMed ID: 30938796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.
    Largent EA; Abera M; Harkins K; Feldman SJ; Uhlmann WR; Roberts JS; Karlawish J;
    J Am Geriatr Soc; 2021 Nov; 69(11):3203-3211. PubMed ID: 34252201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
    Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
    Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of end-of-life preferences in relation to health status and life-events: A cohort study with a 6-year follow-up among holders of an advance directive.
    van Wijmen MPS; Pasman HRW; Twisk JWR; Widdershoven GAM; Onwuteaka-Philipsen BD
    PLoS One; 2018; 13(12):e0209315. PubMed ID: 30562403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study.
    Boccardi M; Altomare D; Ferrari C; Festari C; Guerra UP; Paghera B; Pizzocaro C; Lussignoli G; Geroldi C; Zanetti O; Cotelli MS; Turla M; Borroni B; Rozzini L; Mirabile D; Defanti C; Gennuso M; Prelle A; Gentile S; Morandi A; Vollaro S; Volta GD; Bianchetti A; Conti MZ; Cappuccio M; Carbone P; Bellandi D; Abruzzi L; Bettoni L; Villani D; Raimondi MC; Lanari A; Ciccone A; Facchi E; Di Fazio I; Rozzini R; Boffelli S; Manzoni L; Salvi GP; Cavaliere S; Belotti G; Avanzi S; Pasqualetti P; Muscio C; Padovani A; Frisoni GB;
    JAMA Neurol; 2016 Dec; 73(12):1417-1424. PubMed ID: 27802513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of amyloid PET using
    Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N
    Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
    Vanderschaeghe G; Schaeverbeke J; Bruffaerts R; Vandenberghe R; Dierickx K
    Alzheimers Res Ther; 2017 Dec; 9(1):92. PubMed ID: 29197423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of a family-centered advance care planning intervention for persons with cognitive impairment and their family caregivers on end-of-life care discussions and decisions.
    Huang HL; Lu WR; Huang HL; Liu CL
    PLoS One; 2022; 17(9):e0274096. PubMed ID: 36067182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of an End-of-Life Planning Intervention on the completion of advance directives in homeless persons: a randomized trial.
    Song J; Ratner ER; Wall MM; Bartels DM; Ulvestad N; Petroskas D; West M; Weber-Main AM; Grengs L; Gelberg L
    Ann Intern Med; 2010 Jul; 153(2):76-84. PubMed ID: 20643989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advance Directives as Support of Autonomy for Persons with Dementia? A Pilot Study among Persons with Dementia and Their Informal Caregivers.
    Schmidhuber M; Haeupler S; Marinova-Schmidt V; Frewer A; Kolominsky-Rabas PL
    Dement Geriatr Cogn Dis Extra; 2017; 7(3):328-338. PubMed ID: 29118785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
    Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
    JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.